Nothing Special   »   [go: up one dir, main page]

HU229833B1 - Epothilone d production process, and its use as cytostatic as well as phytosanitary agents - Google Patents

Epothilone d production process, and its use as cytostatic as well as phytosanitary agents Download PDF

Info

Publication number
HU229833B1
HU229833B1 HU0000497A HUP0000497A HU229833B1 HU 229833 B1 HU229833 B1 HU 229833B1 HU 0000497 A HU0000497 A HU 0000497A HU P0000497 A HUP0000497 A HU P0000497A HU 229833 B1 HU229833 B1 HU 229833B1
Authority
HU
Hungary
Prior art keywords
epothilone
spotilon
brain
experiment
polymerization
Prior art date
Application number
HU0000497A
Other languages
English (en)
Inventor
Klaus Gerth
Gerhard Hoefle
Hans Reichenbach
Heinrich Steinmetz
Original Assignee
Biotechnolog Forschung Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26031383&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HU229833(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biotechnolog Forschung Gmbh filed Critical Biotechnolog Forschung Gmbh
Publication of HUP0000497A2 publication Critical patent/HUP0000497A2/hu
Publication of HUP0000497A3 publication Critical patent/HUP0000497A3/hu
Publication of HU229833B1 publication Critical patent/HU229833B1/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/72—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms
    • A01N43/74—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms five-membered rings with one nitrogen atom and either one oxygen atom or one sulfur atom in positions 1,3
    • A01N43/78—1,3-Thiazoles; Hydrogenated 1,3-thiazoles
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/90—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N63/00—Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
    • A01N63/20—Bacteria; Substances produced thereby or obtained therefrom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/16—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing two or more hetero rings
    • C12P17/167—Heterorings having sulfur atoms as ring heteroatoms, e.g. vitamin B1, thiamine nucleus and open chain analogs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
    • C12P17/181—Heterocyclic compounds containing oxygen atoms as the only ring heteroatoms in the condensed system, e.g. Salinomycin, Septamycin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dentistry (AREA)
  • Pest Control & Pesticides (AREA)
  • Agronomy & Crop Science (AREA)
  • Plant Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Environmental Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Silicon Polymers (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Epoxy Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Steroid Compounds (AREA)

Description

(57) Kivonat
A bejelentés D epotilon előállítását írja le Sorangium cellulosum DSM 6773 törzsből kiindulva, melyet adszorbens gyanta jelenlétében tenyésztenek, az adszorbens gyantát a tenyészetből eltávolítják, víz/metanol eleggyel mossák, metanollal eluálják, az eluátumot betöményítve nyers extraktumot kapnak, melyet etil-acetáttal extrahálnak, az extraktumot betöményítik, metanol és hexán között megosztják, a metanolos fázist betöményítve raffinátumot kapnak, a koncentrátumot Sephadex oszlopon frakcionálják, a mikroorganizmus által termelt metabolitokat tartalmazó frakciót C18 típusú reverz fázisú oszlopon metanol/víz eleggyel kromatografálják, a D epotilont tartalmazó frakciót elkülönítik.
1, ábra
A találtóny - egyik Mogvalósltási módja eljárás D apotilon előállítására oly módon, hagy (a) Sorangium oellulosam bők 8773 jelű törzset önmagában ismert módon adsrorbans gyanta jelenlétében tenyésztünk, (fe) az adszorbens gyantát a tenyészetből eltávolítjuk «Is viz/betanol alaggyal mossuk, fc) a mosott adszorbens gyantát metanollal alnáljok, és őz aluétum.oé botóményitve nyers eatrakéumot kapunk/ (d) a kapott koncentrátumot etii-acatátéal extraháljuk/ az eatraktumot feetöményXtják és metanol és bénán között magosatjuk# (e) a metanolon fázist betóményitze raf£Inátumot kapunk, és a kenoantrátumot Saphsdex ossiopon frakolonáljuk, (i) az alkalmazott mikroorganizmus által termált metabolitokat tartalmasé frakóiőt kapunk,
Cg) a kapott frakciót CXá ttpasű rovarz fázisú oszlopon metanol/víz elággyal krometografáljuk, és szekvenciálison egy A epotilont tartalmasé első frakciót és “ egy fe egeim k\u tartakomse oaaodix Hakeitt ™ agy első további epotilont (C apótiIon) tartalmasó ha rmadlk f rako1ót és ~ egy második további epotilont(b apóéiIon) tártaiba tó negyedik frakciót kapunk, és (h) a második további frakció epotiIonját <Ö epotilon) elkülönít jók.
& találmány tárgya továbbá ar alábbi képletü b epetilom
D epotilóó a ™ CHS
B vegyöiet tapasztalati képlete Ο«Κ^0§5 és te 1, Táblázatban megadott ''H-ée *SONMR spektrumai j ell emez hat <b
A D epei. Ilon felhasználható as alábbi 1 képleté vegyületek eléáilltásához# melyek a bk>A~9?/X9 Oáá sz. asabedaltd létráéban ismertetett származék képzési módéterekkel állíthatók elb.
A fenti X» képletben:
R «* R,, ;
R\ R:sf RC R% Rs - H, C©.-elk.ilf Cx~«~&ci 1-ben zoil #
Ca-^-tríaikíl-szilii# benzil# fenil#
Cx-s-alkeni·”#
Cp-aXkil-# hidroxi- és hal o génnel, helyettesített benzil vagy fenilí ahol az R* ~ R^ gyökök közül tette -jCH·?)» csoportot is alkothat# amelyben n jelentése 1 és 6 közötti szám# és a gyökökben lévő alkil- vagy acil-csoportöK egyenes vagy elágazó láncnak?
Y és 1 jelentése azonos vagy különböző lehet és egymástól függetlenül hidrogénatomot# halogénatomot (pl- F# Cl#- Ba vagy 1) # nszaadohalogént (pl. -HCO# -NCS vagy -Xcsoportot.}, 0B~# O~ { Cs.*} ~acil~# 0~ { C?-s) ~ai ki 1 ~ vagy 0benzöil-esoportpt képviselhet, Y és 2 jelentheti egy epoxid oxigénatomját is# mivel oltalmi igényünk az A és B epotilonra nem terjed ki# vagy egy C«C kettős kötés egyik € ~ C köt é s é t a 1 ko t j á k, & 12#·13·~kettős kötés szelektíven - hidrogénezhető.# például katalitikusén vagy diiminnel# ily módon olyan 1 képletü vegyületet kapunk# amelynek képletében Y ~ 2 *« H; vagy ~ epoxiddá alakítható# például dimetil-dioxiránnal vagy egy persawal# ily módon olyan 1 képletü vegyületet kapunk# amelynek képletében Y =» 2 - -0-, vagy dihalidokká# dipszeudohalidokká vagy diazidokká alakítható# ily módon olyan. 1 képletü vegyületet kapunk# amelynek képletében Y és i - Hal# p.szeudo~hal vagy B;;.
A találmány továbbá gyógyászati készítményekre külőnösen citosztatikumokra vonatkozik# amelyek D epotilont vagy epotiionnak egy vagy több szokásos hordozóanyággal és/vagy higitószerrel képetett kombinációiét tartalmazsák,
A találmányt az alábbi kiviteli példákkal rás zlet esebben is bemutatjuk.
D epotlXon
A, Az előállításhoz használt baktérlmi-törzs és &
SB~B~4£ 3S ö<2 », azahadalonfeen ieirtaknak belelnek meg.
a. 1 ap s 2 abada 1 ómba n és egy gyártó 700 I tér£ogatű
B. Blőállítás DSM 6773 tőrmel
1 tenyészetet az ismertetett módon tenyésztünk, fezmentálóberendezésben elhelyezet t, előállító közeget oltunk be vele, A közeg összetétele a: alábbi: 0,8 % keményítő, 0,2 % ssőlőcukor, 0,2 1 szójaliszt, 0,2 % élesztőkivonat, 0,1 % CaCls x 2X0, ö,“ % MgSÖ« x 7 H:í0, 8 mg/l Fe-EOTA, pH ~ 7,4 és kívánt esetbei 15 1 Ambrelíte XAD-16 adszorber gyanta- A fermentálás 30 1 hőmérsékleten 7-1Ö napig tart, a levegőztetést 0,1. NL/isr1 ~ rel végezzük. A rotáció sebességének kontrollálásával a pÖ2~t 30 %“on tartjuk.
C, Izolálás
Az adszorbens gyantát a tenyészettől 0,7 m2, 100 mesh. iyukméretö szörŐ alkalmazásával elválasztjuk, és az égy térfogatára számítva háromszoros mennyiségű, 2:1 arányú viz/metanol eleggyel mosassuk, hogy megszabadítsuk a poláros szennyeződésektől. Az ágy térfogatára számítva négyszeres mennyiségű metanollal történő eluálást követően nyers extraktumot kapunk# amelyet vákuumban a vizes fázis meg jozenésélg bogárólunk«
Ezt háromszor ugyanolyan mennyiségű etil™ acetátfal extraháljuk. A szerves fázist bepárolva 240 g nyers extraktumot kapunk# amelyet a lipofil szennyeződések leválasztása céljából metanol és heptán között megesztank. Az elegyek vákuumban bepároljak- Ily módon 180 g raffinátumot kapunk a metanolos fázisból# amit Sephadex LH~20 jelű oszlopon (20 x 100 cm# 20 mi/perc metanol) három részre frakcionálunk, Az epotilonokat a 240 - 300 perc retehciós idővel kioldódd frakció tartalmazza,# melynek ő'sszmennyisége 7.2 g. Az epotIlonok szétválasztása céljából a frakciót három részletben krőmatögrafáljak Idohroeorb RE-18 oszlopon <15 pm# 10 x 40 om-es oszlop# eluálószer: ISO ml/pere sebességgel átfolyatott# SS:3§ arányé metanol/víz elegy). Először az A és B# majd a € epotilon oldódik ki ss §0-95 perc), majd pedig a D epotilon 100-110 perc retenciós idővel„ Vákuumban történő bepárlés után valamennyi terméket szintélen olaj formájában kapjuk# ö#3 g hozammal.
1» Táblázati 0 epotilon *H~ és C-HMH adatai [b%] OMSO-ban, 300 MHt-en
D epotilon
8 (ppp) C atom 8 (pp.e)
1 170,1
2-Ha 2,35 2 33, 0
2-Hb 2, 30 3 70,0
3-H 4,1 0 4 53,2
3-OH 5,08 5 217,4
6-H 3,11 0 44,4
7-H 3,40 7 75, 5
7-OH 4,46 3 .36, 3
S-H 1,25 9 29,9
3~ Ha Λ í i 10 25, 9
9-Hb 1,30 11 31, 8*
10 -Ha 1,14* 12 130, 2
10-Hb 1,35* 13 120,3
11 -Ha 1, 7 5 14 31,6*
11-Hb 2,10 15 76, 0
12-H 16 137,2
13-H 5,08 1.7 119,2
14 -Ha 2, 30 10 152,1
14-Hb .2, 65 19 117, 7
1S~H 5,29 20 164,3
17-H 6,51 21 IS, 9
I9-H 7,35 22 19,7
21-Hs 2, 65 23 22,5
22~K3 0, 90 24 16, 4
23~H3 1,19 25 Λ $5 í 4
2 4-Hí 1,07 26 22, 3
2S~B3 0,91 27 14, X
.26-¾ 1 ? 03
27-¾ 2,11
* felcserélhető asssi^náeió ··*
Λ találmány eserinti D epotilont és at l^S, dseaehaeonllt.6 példa szerinti A, B, C, E és F epet Hont sejt tenyéeseteken /2.táblásat/ és a pollMerisáció elősegítésére /3, táblázat/ testteltük.
2. Táblázat;
Rpctilsm w 192 & SO? xto-so »'X \x 67? (ng/ssll 1·.' Sál SOS s: S 2 3
tgér kőfcőssöv&tl .sejt t 92$ 1 1. 100 20 20 1,5
Rüssáft daqsmsfcrts snjtvvr3l.sk:
EtoOG (XeukéxdLs) 0,2 0,2 20 3 2 0,3
to S 02 ;1wkésis) 0,2 0,2 20 10 2 o,s
0-033 (lp?qawss«) 0,2 0,2 10 3 1 0,2
SS-3, 1 {mátoyAtoákj 1 0,6 20 12 S 0,5
KB-V1 (cetrix: msXtlrés rák) 0,3 0,3 IS 3 S 0,6
,é~ 4 §§ (vsso rák) ... X,S ISO 20 20 3
toSiO Otáőőrák) 0,7 0,1 20 10 3 0,1
ái Η
ΛΑΑ.·
Paraméter: A kontroj eltelt idő fél“maximális polimerizációja le
20Ö
Reagens Reagens feji
Aj
100
Kontrol18 0
1S(
Spotilon
A ί bS
Epot iIon
v
EpotiIon

Claims (1)

125 ? 6
Spotilon
0 5 —Jt -x
120
106
Spotilon
Mi
5
Spotilon
F
4 9 56
Standard teszt G,9 mg tnbulin/ml és 1 μΜ minta koncentrációval
A polimerizációs kísérlet in vitro kísérlet, melynek során sértés agyából származó tisztított tubulint használunk. A kiértékelést fotörnetriásan végezzük. A polimer!rációt elősegítő anyagok, mint pl. az epotiIonok, csökkentik azt az időt, amely alatt a fél-maximális polimerizaciő végbemegy, vagyis minél rövidébe az idő, annál aktívabb a vegyüiet. W, x, y és z négy önálló kísérlet, a relatív aktivitást az utolsó oszlopban a kontroll %-ában fejezzük ki; a legjobb hatékonyságot itt is a legalacsonyabb értékek jelzik, A hatás-erősség sorrendje meglehetősen pontos egyezést mutat a seittenyés'setekkel végzett kísérlet során tapasztaltakkal.
(b) « AsX^tobmw <e) esXw
«x-íxakfetws'fc b^febs&ényX'tjW a»tM»l é» íwsc&a bfebtfc ttodtolfc ? éss ssskvsaciálix^&n feáfelót kapa
Λ· ·&·
‘ikmtkésit tWfcéáte £eXW#»»á£&«*a «8JY a 8, &a«lafci .ΑSSíSswWí siws
A
SZOLGÁLÓ VÁIJOZ * > v * * > > ♦ ♦» φ * * « φ .»♦ « » x *
Χ . ábra
BgV XAD gyanta eiuábumanak HPLC atalyaise agy Carmen tán© én folyamat végén λ , ábra 1 es e apóexion fai dán óláén. farm ont.lében. A én S epet bion oi agyénak fcatapiaiáao után, Ar nnai i ri gy 48 órás lakúbafás után végeakuk.
ÁWOtATÓM
SZAGA;:A; ;A vOXGYOORODA ? Z.Ö V AAO Q YöZ G y ί ΟΥΥό
Aíf ASOYO 08. Ο.
,vA-?hV\
U] XteKte'noáR
All V O (ÍA'RRN T
Ö8ÁBÁDÁÍ.MX& VföteBöY (RteOA 5 KOVK^RGteteRte'Y te íR sí ’í ábra .8 epotxlon biotranszforeácnősa S: epotxlomjá
AbVOFAl'EÁl
ÉÉÁSáD/p Ab ÉS VÉDJbSY ÉRM'b dVORÉiY
HU0000497A 1996-11-18 1997-11-18 Epothilone d production process, and its use as cytostatic as well as phytosanitary agents HU229833B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19647580 1996-11-18
DE19707506 1997-02-25
PCT/EP1997/006442 WO1998022461A1 (de) 1996-11-18 1997-11-18 Epothilone c, d, e und f, deren herstellung und deren verwendung als cytostatische mittel bzw. als pflanzenschutzmittel

Publications (3)

Publication Number Publication Date
HUP0000497A2 HUP0000497A2 (hu) 2000-06-28
HUP0000497A3 HUP0000497A3 (en) 2001-10-29
HU229833B1 true HU229833B1 (en) 2014-09-29

Family

ID=26031383

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0000497A HU229833B1 (en) 1996-11-18 1997-11-18 Epothilone d production process, and its use as cytostatic as well as phytosanitary agents

Country Status (24)

Country Link
US (6) US7067544B2 (hu)
EP (2) EP0941227B2 (hu)
JP (1) JP4274583B2 (hu)
KR (1) KR100538095B1 (hu)
CN (2) CN1196698C (hu)
AT (2) ATE408612T1 (hu)
AU (1) AU753546B2 (hu)
BR (1) BR9713363B1 (hu)
CA (1) CA2269118C (hu)
CY (1) CY2542B1 (hu)
CZ (2) CZ296164B6 (hu)
DE (2) DE59711647D1 (hu)
DK (2) DK0941227T5 (hu)
ES (2) ES2221692T5 (hu)
HK (2) HK1022314A1 (hu)
HU (1) HU229833B1 (hu)
IL (1) IL129558A (hu)
NO (1) NO319984B1 (hu)
NZ (1) NZ335383A (hu)
PL (1) PL193229B1 (hu)
PT (2) PT941227E (hu)
RU (1) RU2198173C2 (hu)
TW (1) TW408119B (hu)
WO (1) WO1998022461A1 (hu)

Families Citing this family (176)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1186606E (pt) 1995-11-17 2004-08-31 Biotechnolog Forschung Mbh Gbf Derivados do epotilone sua preparacao e utilizacao
US5969145A (en) * 1996-08-30 1999-10-19 Novartis Ag Process for the production of epothilones and intermediate products within the process
AU753546B2 (en) 1996-11-18 2002-10-24 Helmholtz-Zentrum Fuer Infektionsforschung Gmbh Epothilone C, D, E and F, production process, and their use as cytostatic as well as phytosanitary agents
EP0977563B1 (en) * 1996-12-03 2005-10-12 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6867305B2 (en) 1996-12-03 2005-03-15 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6204388B1 (en) 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6441186B1 (en) * 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
US6380394B1 (en) 1996-12-13 2002-04-30 The Scripps Research Institute Epothilone analogs
US6660758B1 (en) 1996-12-13 2003-12-09 The Scripps Research Institute Epothilone analogs
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
US6320045B1 (en) 1997-12-04 2001-11-20 Bristol-Myers Squibb Company Process for the reduction of oxiranyl epothilones to olefinic epothilones
US6365749B1 (en) 1997-12-04 2002-04-02 Bristol-Myers Squibb Company Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
US6683100B2 (en) 1999-01-19 2004-01-27 Novartis Ag Organic compounds
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
FR2775187B1 (fr) 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
US6380395B1 (en) 1998-04-21 2002-04-30 Bristol-Myers Squibb Company 12, 13-cyclopropane epothilone derivatives
US6498257B1 (en) * 1998-04-21 2002-12-24 Bristol-Myers Squibb Company 2,3-olefinic epothilone derivatives
DE19820599A1 (de) 1998-05-08 1999-11-11 Biotechnolog Forschung Gmbh Epothilonderivate, Verfahren zu deren Herstellung und deren Verwendung
DE19826988A1 (de) * 1998-06-18 1999-12-23 Biotechnolog Forschung Gmbh Epothilon-Nebenkomponenten
NZ508326A (en) * 1998-06-18 2003-10-31 Novartis Ag A polyketide synthase and non ribosomal peptide synthase genes, isolated from a myxobacterium, necessary for synthesis of epothiones A and B
DE19846493A1 (de) * 1998-10-09 2000-04-13 Biotechnolog Forschung Gmbh DNA-Sequenzen für die enzymatische Synthese von Polyketid- oder Heteropolyketidverbindungen
US6410301B1 (en) 1998-11-20 2002-06-25 Kosan Biosciences, Inc. Myxococcus host cells for the production of epothilones
KR100716272B1 (ko) 1998-11-20 2007-05-09 코산 바이오사이언시즈, 인코포레이티드 에포틸론 및 에포틸론 유도체의 생산을 위한 재조합 방법 및 물질
US6780620B1 (en) 1998-12-23 2004-08-24 Bristol-Myers Squibb Company Microbial transformation method for the preparation of an epothilone
CA2356360A1 (en) * 1998-12-23 2000-07-06 Bristol-Myers Squibb Company Microbial transformation method for the preparation of an epothilone
US6596875B2 (en) 2000-02-07 2003-07-22 James David White Method for synthesizing epothilones and epothilone analogs
CN1205208C (zh) * 1999-02-22 2005-06-08 生物技术研究股份有限公司 C－21修饰的环氧噻酮类化合物
US6291684B1 (en) 1999-03-29 2001-09-18 Bristol-Myers Squibb Company Process for the preparation of aziridinyl epothilones from oxiranyl epothilones
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
KR100722344B1 (ko) 1999-04-15 2007-05-29 브리스톨-마이어스스퀴브컴파니 환형 단백질 티로신 키나제 억제제
EP1229934B1 (en) 1999-10-01 2014-03-05 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
US6518421B1 (en) * 2000-03-20 2003-02-11 Bristol-Myers Squibb Company Process for the preparation of epothilone analogs
US6593115B2 (en) 2000-03-24 2003-07-15 Bristol-Myers Squibb Co. Preparation of epothilone intermediates
US6998256B2 (en) 2000-04-28 2006-02-14 Kosan Biosciences, Inc. Methods of obtaining epothilone D using crystallization and /or by the culture of cells in the presence of methyl oleate
US6589968B2 (en) 2001-02-13 2003-07-08 Kosan Biosciences, Inc. Epothilone compounds and methods for making and using the same
ES2254493T3 (es) * 2000-04-28 2006-06-16 Kosan Biosciences, Inc. Produccion heterologa de policetidos.
UA75365C2 (en) * 2000-08-16 2006-04-17 Bristol Myers Squibb Co Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
GB0029895D0 (en) * 2000-12-07 2001-01-24 Novartis Ag Organic compounds
CA2434566A1 (en) 2001-01-25 2002-08-15 Timothy M. Malloy Parenteral formulation containing epothilone analogs
HU229349B1 (en) 2001-01-25 2013-11-28 Bristol Myers Squibb Co Methods for preparation of pharmaceutical composition containing epothilone analogs useful for treatment of cancer
WO2002058699A1 (en) * 2001-01-25 2002-08-01 Bristol-Myers Squibb Company Pharmaceutical forms of epothilones for oral administration
US6893859B2 (en) 2001-02-13 2005-05-17 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same
KR20040028720A (ko) 2001-02-20 2004-04-03 브리스톨-마이어스스퀴브컴파니 치료불응성 종양 치료용 에포틸론 유도체
IL156988A0 (en) 2001-02-20 2004-02-08 Bristol Myers Squibb Co Pharmaceutical compositions containing epothilone derivatives
EP1364040B1 (en) 2001-02-27 2006-05-03 Gesellschaft für biotechnologische Forschung mbH (GBF) Degradation of epothilones and ethynyl substituted epothilones
SK287489B6 (sk) 2001-02-27 2010-11-08 Novartis Ag Kombinácia inhibítora PDGF receptorovej tyrozínkinázy a derivátu epotilónu, farmaceutická kompozícia s jej obsahom a jej použitie
KR20040025904A (ko) 2001-03-14 2004-03-26 브리스톨-마이어스 스큅 컴퍼니 증식성 질환의 치료를 위한 에포틸론 유사체 및화학치료제의 병용
MXPA03010909A (es) 2001-06-01 2004-02-17 Bristol Myers Squibb Co Derivados de epotilona.
TWI315982B (en) 2001-07-19 2009-10-21 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
TWI287986B (en) * 2001-12-13 2007-10-11 Novartis Ag Use of Epothilones for the treatment of the carcinoid syndrome
US6884608B2 (en) 2001-12-26 2005-04-26 Bristol-Myers Squibb Company Compositions and methods for hydroxylating epothilones
TWI341728B (en) 2002-01-14 2011-05-11 Novartis Ag Combinations comprising epothilones and anti-metabolites
TW200303202A (en) 2002-02-15 2003-09-01 Bristol Myers Squibb Co Method of preparation of 21-amino epothilone derivatives
DE60330651D1 (en) 2002-03-12 2010-02-04 Bristol Myers Squibb Co C3-cyanoepothilonderivate
AU2003218107A1 (en) 2002-03-12 2003-09-29 Bristol-Myers Squibb Company C12-cyano epothilone derivatives
TW200403994A (en) 2002-04-04 2004-03-16 Bristol Myers Squibb Co Oral administration of EPOTHILONES
TW200400191A (en) 2002-05-15 2004-01-01 Bristol Myers Squibb Co Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
US7405234B2 (en) 2002-05-17 2008-07-29 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
WO2003105828A1 (en) 2002-06-14 2003-12-24 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
AU2003251902B2 (en) * 2002-07-29 2008-03-06 Merck Sharp & Dohme Llc Tiacumicin production
ATE450534T1 (de) * 2002-08-23 2009-12-15 Sloan Kettering Inst Cancer Synthese von epothilonen, zwischenprodukte davon, analoga und ihre verwendung
RU2368661C2 (ru) 2002-09-23 2009-09-27 Бристол-Маерс Сквибб Компани Способы получения, выделения и очистки эпотилона b и рентгеноструктурные кристаллические структуры эпотилона в
PT1553938E (pt) * 2002-10-15 2007-03-30 Univ Louisiana State Utilização de derivados de epotilona para o tratamento do hiperparatiroidismo
EP1567487A4 (en) 2002-11-15 2005-11-16 Bristol Myers Squibb Co OPEN-CHAINED, PROLYL-FROSTED MODULATORS OF ANDROGEN RECEPTOR FUNCTION
CN100359014C (zh) * 2003-01-28 2008-01-02 北京华昊中天生物技术有限公司 一类新型埃坡霉素化合物及其制备方法和用途
US20050171167A1 (en) 2003-11-04 2005-08-04 Haby Thomas A. Process and formulation containing epothilones and analogs thereof
EP1559447A1 (en) 2004-01-30 2005-08-03 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of epothilones in the treatment of neuronal connectivity defects such as schizophrenia and autism
US7820702B2 (en) 2004-02-04 2010-10-26 Bristol-Myers Squibb Company Sulfonylpyrrolidine modulators of androgen receptor function and method
US7378426B2 (en) 2004-03-01 2008-05-27 Bristol-Myers Squibb Company Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3
US7696241B2 (en) 2004-03-04 2010-04-13 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
US7625923B2 (en) 2004-03-04 2009-12-01 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
ES2396195T3 (es) 2004-04-07 2013-02-19 Novartis Ag Inhibidores de IAP
US10675326B2 (en) 2004-10-07 2020-06-09 The Board Of Trustees Of The University Of Illinois Compositions comprising cupredoxins for treating cancer
BRPI0518286A2 (pt) * 2004-11-18 2008-11-11 Bristol Myers Squibb Co microesfera com revestimento entÉrico contendo ixabepilona e sua preparaÇço
EP1824458A1 (en) * 2004-11-18 2007-08-29 Bristol-Myers Squibb Company Enteric coated bead comprising epothilone or an epothilone analog, and preparation and administration thereof
US20060121511A1 (en) 2004-11-30 2006-06-08 Hyerim Lee Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
US20080255149A1 (en) 2005-09-27 2008-10-16 Novartis Ag Carboxyamine Compounds and Methods of Use Thereof
NO20220050A1 (no) 2005-11-21 2008-08-12 Novartis Ag Neuroendokrin tumorbehandling
GB0605120D0 (en) 2006-03-14 2006-04-26 Novartis Ag Organic Compounds
CA2647565A1 (en) 2006-03-31 2007-10-18 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents
WO2007115289A2 (en) 2006-04-05 2007-10-11 Novartis Ag Combinations comprising bcr-abl/c-kit/pdgf-r tk inhibitors for treating cancer
KR20080108517A (ko) 2006-04-05 2008-12-15 노파르티스 아게 암을 치료하기 위한 치료제의 조합물
KR20090007635A (ko) 2006-05-09 2009-01-19 노파르티스 아게 철 킬레이터 및 항-신생물 약제를 포함하는 조합물 및 그의용도
RU2009115954A (ru) 2006-09-29 2010-11-10 Новартис АГ (CH) Пиразолопиримидины в качестве ингибиторов липидной киназы р13к
JP2010511408A (ja) 2006-12-04 2010-04-15 ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ 癌をＣｐＧリッチＤＮＡおよびキュプレドキシンで治療するための組成物および方法
JP2010518123A (ja) 2007-02-08 2010-05-27 ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ 癌をキュプレドキシンで予防するための組成物および方法
AR065335A1 (es) 2007-02-15 2009-06-03 Novartis Ag Combinaciones de agentes terapeuticos para el tratamiento de cancer
AU2009228765B2 (en) 2008-03-24 2012-05-31 Novartis Ag Arylsulfonamide-based matrix metalloprotease inhibitors
CA2719477C (en) 2008-03-26 2016-11-08 Novartis Ag Hydroxamate-based inhibitors of deacetylases b
CN101362784A (zh) * 2008-10-06 2009-02-11 山东大学 埃博霉素苷类化合物和以其为活性成分的组合物及其应用
WO2010083617A1 (en) 2009-01-21 2010-07-29 Oncalis Ag Pyrazolopyrimidines as protein kinase inhibitors
TW201031406A (en) 2009-01-29 2010-09-01 Novartis Ag Substituted benzimidazoles for the treatment of astrocytomas
ES2475945T3 (es) 2009-06-26 2014-07-11 Novartis Ag Derivados imidazolidin-2 -ona 1,3-disustituida como inhibidores de CYP 17
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
CA2770873A1 (en) 2009-08-12 2011-02-17 Novartis Ag Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
KR20120089463A (ko) 2009-08-20 2012-08-10 노파르티스 아게 헤테로시클릭 옥심 화합물
US20120149661A1 (en) 2009-08-26 2012-06-14 Novartis Ag Tetra-substituted heteroaryl compounds and their use as mdm2 and/or mdm4 modulators
PE20121471A1 (es) 2009-11-04 2012-11-01 Novartis Ag Derivados de sulfonamida heterociclicos utiles como inhibidores de mek
WO2011070030A1 (en) 2009-12-08 2011-06-16 Novartis Ag Heterocyclic sulfonamide derivatives
CU24130B1 (es) 2009-12-22 2015-09-29 Novartis Ag Isoquinolinonas y quinazolinonas sustituidas
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
CA2927832C (en) 2010-05-18 2021-03-23 Cerulean Pharma Inc. Cyclodextrin-containing polymer-therapeutic agent conjugates and their use
UA112517C2 (uk) 2010-07-06 2016-09-26 Новартіс Аг Тетрагідропіридопіримідинові похідні
JP2013537210A (ja) 2010-09-16 2013-09-30 ノバルティス アーゲー １７α−ヒドロキシラーゼ／Ｃ１７，２０−リアーゼ阻害剤
JP5889337B2 (ja) 2011-01-20 2016-03-22 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム Ｍｒｉマーカー、送達および抜取りシステムならびにこれらの製造方法および使用方法
JP2014505088A (ja) 2011-02-10 2014-02-27 ノバルティス アーゲー Ｃ−ＭＥＴチロシンキナーゼ阻害剤としての［１，２，４］トリアゾロ［４，３−ｂ］ピリダジン化合物
JP6002210B2 (ja) 2011-04-28 2016-10-05 ノバルティス アーゲー １７α−ヒドロキシラーゼ／Ｃ１７，２０−リアーゼ阻害剤
CA2838029A1 (en) 2011-06-09 2012-12-13 Novartis Ag Heterocyclic sulfonamide derivatives
RU2617402C2 (ru) 2011-06-10 2017-04-25 Мерсана Терапьютикс, Инк. Конъюгаты белок-полимер-лекарственное средство
EP2721007B1 (en) 2011-06-20 2015-04-29 Novartis AG Cyclohexyl isoquinolinone compounds
EP2721008B1 (en) 2011-06-20 2015-04-29 Novartis AG Hydroxy substituted isoquinolinone derivatives as p53 (mdm2 or mdm4) inhibitors
EP2723740A1 (en) 2011-06-27 2014-04-30 Novartis AG Solid forms and salts of tetrahydro-pyrido-pyrimidine derivatives
CN102863474A (zh) 2011-07-09 2013-01-09 陈小平 一类治疗细胞增殖性疾病的铂化合物、其制备方法和应用
CA2848809A1 (en) 2011-09-15 2013-03-21 Novartis Ag 6-substituted 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyradines as c-met tyrosine kinase
CN102993239A (zh) 2011-09-19 2013-03-27 陈小平 离去基团含氨基或烷胺基的丁二酸衍生物的铂类化合物
JP5992054B2 (ja) 2011-11-29 2016-09-14 ノバルティス アーゲー ピラゾロピロリジン化合物
WO2013093850A1 (en) 2011-12-22 2013-06-27 Novartis Ag Quinoline derivatives
JP5903499B2 (ja) 2011-12-22 2016-04-13 ノバルティス アーゲー ジヒドロ−ベンゾ−オキサジンおよびジヒドロ−ピリド−オキサジン誘導体
WO2013096059A1 (en) 2011-12-23 2013-06-27 Novartis Ag Compounds for inhibiting the interaction of bcl2 with binding partners
KR20140107578A (ko) 2011-12-23 2014-09-04 노파르티스 아게 Bcl2와 결합 파트너의 상호작용을 억제하기 위한 화합물
US20140357666A1 (en) 2011-12-23 2014-12-04 Novartis Ag Compounds for inhibiting the interaction of bcl2 with binding partners
MX2014007729A (es) 2011-12-23 2015-01-12 Novartis Ag Compuestos para inhibir la interaccion de bcl2 con los componentes de enlace.
BR112014015339A8 (pt) 2011-12-23 2017-06-13 Novartis Ag compostos para inibição da interação de bcl2 com parceiros de ligação
KR101372563B1 (ko) 2011-12-26 2014-03-14 주식회사 삼양바이오팜 에포틸론 함유물질로부터 에포틸론 ａ와 ｂ의 추출 및 정제 방법
UY34591A (es) 2012-01-26 2013-09-02 Novartis Ag Compuestos de imidazopirrolidinona
MX2014013373A (es) 2012-05-15 2015-08-14 Novartis Ag Derivados de benzamida para inhibir la actividad de abl1, abl2 y bcr-abl1.
PT2861579T (pt) 2012-05-15 2018-04-27 Novartis Ag Derivados de benzamida para inibir a atividade de abl1, abl2 e bcr-abl
BR112014027584B1 (pt) 2012-05-15 2023-01-24 Novartis Ag Uso de inibidores da atividade de abl1, abl2 e bcr-abl1, e composição farmacêutica
JP6204975B2 (ja) 2012-05-15 2017-09-27 ノバルティス アーゲー Ａｂｌ１、ａｂｌ２およびｂｃｒ−ａｂｌ１の活性を阻害するためのベンズアミド誘導体
CN104321325B (zh) 2012-05-24 2016-11-16 诺华股份有限公司 吡咯并吡咯烷酮化合物
EP2861256B1 (en) 2012-06-15 2019-10-23 The Brigham and Women's Hospital, Inc. Compositions for treating cancer and methods for making the same
CN107434803B (zh) 2012-10-02 2020-05-05 吉利德科学公司 组蛋白去甲基化酶抑制剂
WO2014075391A1 (zh) 2012-11-17 2014-05-22 北京市丰硕维康技术开发有限责任公司 离去基团是含氨基或烷氨基的丙二酸衍生物的铂类化合物
TW201422625A (zh) 2012-11-26 2014-06-16 Novartis Ag 二氫－吡啶并－□衍生物之固體形式
EP2928504B1 (en) 2012-12-10 2019-02-20 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
EP2931316B1 (en) 2012-12-12 2019-02-20 Mersana Therapeutics, Inc. Hydroxyl-polymer-drug-protein conjugates
JO3464B1 (ar) 2013-01-15 2020-07-05 Astellas Pharma Europe Ltd التركيبات الخاصة بمركبات التياكوميسين
US9403827B2 (en) 2013-01-22 2016-08-02 Novartis Ag Substituted purinone compounds
WO2014115080A1 (en) 2013-01-22 2014-07-31 Novartis Ag Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the p53/mdm2 interaction
WO2014128612A1 (en) 2013-02-20 2014-08-28 Novartis Ag Quinazolin-4-one derivatives
KR102229992B1 (ko) 2013-02-27 2021-03-19 에피테라퓨틱스 에이피에스 히스톤 데메틸라아제의 저해제
US20150018376A1 (en) 2013-05-17 2015-01-15 Novartis Ag Pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide derivatives and use thereof
WO2014198645A1 (en) 2013-06-11 2014-12-18 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer comprising a mps-1 kinase inhibitor and a mitotic inhibitor
UY35675A (es) 2013-07-24 2015-02-27 Novartis Ag Derivados sustituidos de quinazolin-4-ona
WO2015022664A1 (en) 2013-08-14 2015-02-19 Novartis Ag Compounds and compositions as inhibitors of mek
WO2015022663A1 (en) 2013-08-14 2015-02-19 Novartis Ag Compounds and compositions as inhibitors of mek
US9227969B2 (en) 2013-08-14 2016-01-05 Novartis Ag Compounds and compositions as inhibitors of MEK
US9670194B2 (en) 2013-09-22 2017-06-06 Calitor Sciences, Llc Substituted aminopyrimidine compounds and methods of use
CA2926586C (en) 2013-10-11 2020-04-07 Mersana Therapeutics, Inc. Polymeric scaffold based on phf for targeted drug delivery
US10316080B2 (en) 2013-10-11 2019-06-11 Asana Biosciences, Llc Protein-polymer-drug conjugates
EP3122728A4 (en) 2014-03-28 2017-10-25 Calitor Sciences, LLC Substituted heteroaryl compounds and methods of use
JP2017512804A (ja) 2014-03-31 2017-05-25 ギリアード サイエンシーズ， インコーポレイテッド ヒストン脱メチル化酵素の阻害剤
MX2016012893A (es) 2014-04-03 2017-05-12 Invictus Oncology Pvt Ltd Sustancias terapéuticas combinadas supramoleculares.
JP2017526675A (ja) 2014-08-27 2017-09-14 ギリアード サイエンシーズ， インコーポレイテッド ヒストンデメチラーゼを阻害するための化合物および方法
WO2017044434A1 (en) 2015-09-11 2017-03-16 Sunshine Lake Pharma Co., Ltd. Substituted heteroaryl compounds and methods of use
WO2018004338A1 (en) 2016-06-27 2018-01-04 Tagworks Pharmaceuticals B.V. Cleavable tetrazine used in bio-orthogonal drug activation
US11135307B2 (en) 2016-11-23 2021-10-05 Mersana Therapeutics, Inc. Peptide-containing linkers for antibody-drug conjugates
JP7320458B2 (ja) 2017-06-22 2023-08-03 メルサナ セラピューティクス インコーポレイテッド 薬物担持ポリマースキャフォールドおよびタンパク質－ポリマー－薬物コンジュゲートを製造する方法
EP3710006A4 (en) 2017-11-19 2021-09-01 Sunshine Lake Pharma Co., Ltd. SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR METHODS OF USE
WO2019143874A1 (en) 2018-01-20 2019-07-25 Sunshine Lake Pharma Co., Ltd. Substituted aminopyrimidine compounds and methods of use
DK3788032T3 (da) 2018-05-04 2024-04-15 Tagworks Pharmaceuticals B V Forbindelser omfattende en linker til øgning af transcyklooctenstabilitet
US20210299286A1 (en) 2018-05-04 2021-09-30 Tagworks Pharmaceuticals B.V. Tetrazines for high click conjugation yield in vivo and high click release yield
WO2020092385A1 (en) 2018-10-29 2020-05-07 Mersana Therapeutics, Inc. Cysteine engineered antibody-drug conjugates with peptide-containing linkers
FR3087650B1 (fr) 2018-10-31 2021-01-29 Bio Even Flavine adenine dinucleotide (fad) pour son utilisation pour la prevention et/ou le traitement de cancer
EP3983363B1 (en) 2019-06-17 2024-04-10 Tagworks Pharmaceuticals B.V. Compounds for fast and efficient click release
IL289094A (en) 2019-06-17 2022-02-01 Tagworks Pharmaceuticals B V Tetrazines for increasing the speed and yield of the "click release" reaction
WO2023031445A2 (en) 2021-09-06 2023-03-09 Veraxa Biotech Gmbh Novel aminoacyl-trna synthetase variants for genetic code expansion in eukaryotes
EP4186529A1 (en) 2021-11-25 2023-05-31 Veraxa Biotech GmbH Improved antibody-payload conjugates (apcs) prepared by site-specific conjugation utilizing genetic code expansion
KR20240105469A (ko) 2021-11-25 2024-07-05 베락사 바이오테크 게엠베하 유전자 코드 확장을 이용하는 부위-특이적 접합에 의해 제조되는 개선된 항체-페이로드 접합체 (apc)
AU2022404647A1 (en) 2021-12-08 2024-06-13 European Molecular Biology Laboratory Hydrophilic tetrazine-functionalized payloads for preparation of targeting conjugates
EP4314031B1 (en) 2022-02-15 2024-03-13 Tagworks Pharmaceuticals B.V. Masked il12 protein
WO2024013723A1 (en) 2022-07-15 2024-01-18 Pheon Therapeutics Ltd Antibody drug conjugates that bind cdcp1 and uses thereof
WO2024080872A1 (en) 2022-10-12 2024-04-18 Tagworks Pharmaceuticals B.V. Strained bicyclononenes
WO2024153789A1 (en) 2023-01-20 2024-07-25 Basf Se Stabilized biopolymer composition, their manufacture and use
WO2024191293A1 (en) 2023-03-10 2024-09-19 Tagworks Pharmaceuticals B.V. Trans-cyclooctene with improved t-linker

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0358606A3 (de) 1988-09-09 1990-10-31 Gesellschaft für Biotechnologische Forschung mbH (GBF) Mikrobiologisches Verfahren zur Herstellung agrarchemisch verwendbarer mikrobizider makrozyklischer Lactonderivate
GB8909737D0 (en) 1989-04-27 1989-06-14 Shell Int Research Thiazole derivatives
DE4138042C2 (de) * 1991-11-19 1993-10-14 Biotechnolog Forschung Gmbh Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel
US5665767A (en) 1993-03-05 1997-09-09 Hexal Pharma Gmbh Crystalline cyclodextrin complexes of ranitidine hydrochloride, process for their preparation and pharmaceutical compositions containing the same
WO1995018798A1 (en) 1994-01-11 1995-07-13 The Scripps Research Institute Chemical switching of taxo-diterpenoids between low solubility active forms and high solubility inactive forms
DE19639456A1 (de) 1996-09-25 1998-03-26 Biotechnolog Forschung Gmbh Epothilon-Derivate, Herstellung und Mittel
PT1186606E (pt) 1995-11-17 2004-08-31 Biotechnolog Forschung Mbh Gbf Derivados do epotilone sua preparacao e utilizacao
DE19542986A1 (de) * 1995-11-17 1997-05-22 Biotechnolog Forschung Gmbh Epothilon-Derivate und deren Verwendung
DE19645361A1 (de) 1996-08-30 1998-04-30 Ciba Geigy Ag Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B, Teil II
DE19645362A1 (de) 1996-10-28 1998-04-30 Ciba Geigy Ag Verfahren zur Herstellung von Epothilon A und B und Derivaten
NZ334821A (en) 1996-08-30 2000-12-22 Novartis Ag Method for producing epothilones
DE19636343C1 (de) 1996-08-30 1997-10-23 Schering Ag Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B
US5969145A (en) * 1996-08-30 1999-10-19 Novartis Ag Process for the production of epothilones and intermediate products within the process
AU753546B2 (en) * 1996-11-18 2002-10-24 Helmholtz-Zentrum Fuer Infektionsforschung Gmbh Epothilone C, D, E and F, production process, and their use as cytostatic as well as phytosanitary agents
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
US6204388B1 (en) * 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
EP0977563B1 (en) 1996-12-03 2005-10-12 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
US6660758B1 (en) 1996-12-13 2003-12-09 The Scripps Research Institute Epothilone analogs
US6380394B1 (en) * 1996-12-13 2002-04-30 The Scripps Research Institute Epothilone analogs
DE19701758A1 (de) 1997-01-20 1998-07-23 Wessjohann Ludgar A Dr Epothilone-Synthesebausteine
CN1544436A (zh) * 1997-02-25 2004-11-10 ���＼���о����޹�˾��GBF�� 3，7-保护的环氧噻嗪酮-n-氧化物及其制备方法
US5828449A (en) 1997-02-26 1998-10-27 Acuity Imaging, Llc Ring illumination reflective elements on a generally planar surface
DE19713970B4 (de) 1997-04-04 2006-08-31 R&D-Biopharmaceuticals Gmbh Epothilone-Synthesebausteine II - Prenylderivate
EP0975622B1 (de) 1997-04-18 2002-10-09 Studiengesellschaft Kohle mbH Selektive olefinmetathese von bi- oder polyfunktionellen substraten in komprimiertem kohlendioxid als reaktionsmedium
DE19720312A1 (de) 1997-05-15 1998-11-19 Hoechst Ag Zubereitung mit erhöhter in vivo Verträglichkeit
DE19821954A1 (de) 1997-05-15 1998-11-19 Biotechnolog Forschung Gmbh Verfahren zur Herstellung eines Epothilon-Derivats
DE19726627A1 (de) 1997-06-17 1998-12-24 Schering Ag Zwischenprodukte, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von Epothilon
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
EP1001951B1 (de) 1997-07-16 2002-09-25 Schering Aktiengesellschaft Thiazolderivate, verfahren zur herstellung und verwendung
ATE368036T1 (de) 1997-08-09 2007-08-15 Bayer Schering Pharma Ag Neue epothilon-derivate, verfahren zu deren herstellung und ihre pharmazeutische verwendung
CA2320182C (en) 1998-02-05 2008-11-25 Novartis Ag Compositions containing organic compounds
US6194181B1 (en) * 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
WO1999043653A1 (en) 1998-02-25 1999-09-02 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues therof
FR2775187B1 (fr) 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
DE19826988A1 (de) * 1998-06-18 1999-12-23 Biotechnolog Forschung Gmbh Epothilon-Nebenkomponenten
WO2000000485A1 (de) 1998-06-30 2000-01-06 Schering Aktiengesellschaft Epothilon-derivate, verfahren zu deren herstellung, zwischenprodukte und ihre pharmazeutische verwendung
US6410301B1 (en) * 1998-11-20 2002-06-25 Kosan Biosciences, Inc. Myxococcus host cells for the production of epothilones
KR100716272B1 (ko) 1998-11-20 2007-05-09 코산 바이오사이언시즈, 인코포레이티드 에포틸론 및 에포틸론 유도체의 생산을 위한 재조합 방법 및 물질
EP1140944B1 (en) 1998-12-22 2003-08-27 Novartis AG Epothilone derivatives and their use as antitumor agents
US6780620B1 (en) 1998-12-23 2004-08-24 Bristol-Myers Squibb Company Microbial transformation method for the preparation of an epothilone
US6596875B2 (en) * 2000-02-07 2003-07-22 James David White Method for synthesizing epothilones and epothilone analogs
YU59001A (sh) 1999-02-18 2005-07-19 Schering Ag. 16-halogen-epotilon-derivati, postupak za njihovo dobijanje i njihova farmaceutska primena
CN1205208C (zh) * 1999-02-22 2005-06-08 生物技术研究股份有限公司 C－21修饰的环氧噻酮类化合物
US6211412B1 (en) * 1999-03-29 2001-04-03 The University Of Kansas Synthesis of epothilones
PE20010116A1 (es) 1999-04-30 2001-02-15 Schering Ag Derivados de 6-alquenil-, 6-alquinil- y 6-epoxi-epotilona, procedimientos para su preparacion
TWI310684B (en) * 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
US6589968B2 (en) * 2001-02-13 2003-07-08 Kosan Biosciences, Inc. Epothilone compounds and methods for making and using the same
US6489314B1 (en) * 2001-04-03 2002-12-03 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same
US6906188B2 (en) * 2001-04-30 2005-06-14 State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University Method for synthesizing epothilones and epothilone analogs
WO2003029195A1 (fr) * 2001-09-28 2003-04-10 Sumika Fine Chemicals Co., Ltd. Intermediaires pour l'elaboration d'un derive de l'epothilone, et leur procede de production
US6884608B2 (en) * 2001-12-26 2005-04-26 Bristol-Myers Squibb Company Compositions and methods for hydroxylating epothilones
TW200303202A (en) 2002-02-15 2003-09-01 Bristol Myers Squibb Co Method of preparation of 21-amino epothilone derivatives
US6921769B2 (en) * 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
RU2368661C2 (ru) 2002-09-23 2009-09-27 Бристол-Маерс Сквибб Компани Способы получения, выделения и очистки эпотилона b и рентгеноструктурные кристаллические структуры эпотилона в

Also Published As

Publication number Publication date
US7067544B2 (en) 2006-06-27
PT1367057E (pt) 2008-12-04
EP0941227A1 (de) 1999-09-15
NZ335383A (en) 2000-10-27
DK1367057T3 (da) 2009-01-19
US20080293784A1 (en) 2008-11-27
PT941227E (pt) 2004-08-31
IL129558A (en) 2001-10-31
CA2269118A1 (en) 1998-05-28
CN1680370A (zh) 2005-10-12
ES2221692T3 (es) 2005-01-01
DK0941227T5 (da) 2009-10-05
EP1367057B1 (de) 2008-09-17
NO992338L (no) 1999-05-14
US7759375B2 (en) 2010-07-20
US20090247592A1 (en) 2009-10-01
BR9713363B1 (pt) 2011-02-08
CN1196698C (zh) 2005-04-13
NO319984B1 (no) 2005-10-10
CZ303422B6 (cs) 2012-09-05
JP2001504474A (ja) 2001-04-03
US8076490B2 (en) 2011-12-13
WO1998022461A1 (de) 1998-05-28
ATE408612T1 (de) 2008-10-15
DK0941227T4 (da) 2008-05-19
PL333435A1 (en) 1999-12-06
DE59711647D1 (de) 2004-06-24
EP0941227B2 (de) 2009-10-14
PL193229B1 (pl) 2007-01-31
KR20000053308A (ko) 2000-08-25
TW408119B (en) 2000-10-11
CZ175099A3 (cs) 1999-09-15
KR100538095B1 (ko) 2005-12-21
EP1367057A1 (de) 2003-12-03
NO992338D0 (no) 1999-05-14
AU5483798A (en) 1998-06-10
RU2198173C2 (ru) 2003-02-10
CZ296164B6 (cs) 2006-01-11
ES2221692T5 (es) 2009-12-14
CA2269118C (en) 2012-05-29
ES2221692T4 (es) 2005-10-01
AU753546B2 (en) 2002-10-24
EP0941227B9 (de) 2005-05-04
IL129558A0 (en) 2000-02-29
CY2542B1 (en) 2006-06-28
JP4274583B2 (ja) 2009-06-10
US20060264482A1 (en) 2006-11-23
US20110136185A1 (en) 2011-06-09
HUP0000497A2 (hu) 2000-06-28
ES2312695T3 (es) 2009-03-01
HUP0000497A3 (en) 2001-10-29
CN1237970A (zh) 1999-12-08
HK1022314A1 (en) 2000-08-04
US7846952B2 (en) 2010-12-07
DK0941227T3 (da) 2004-06-28
ATE267197T1 (de) 2004-06-15
DE59712968D1 (de) 2008-10-30
CN100344627C (zh) 2007-10-24
EP0941227B1 (de) 2004-05-19
HK1083832A1 (en) 2006-07-14
US20050090535A1 (en) 2005-04-28
BR9713363A (pt) 2000-01-25
US20090270466A1 (en) 2009-10-29

Similar Documents

Publication Publication Date Title
HU229833B1 (en) Epothilone d production process, and its use as cytostatic as well as phytosanitary agents
ES2218328T5 (es) Derivados de epotilón, su preparación y utilización.
JP2002514649A (ja) エポチロン誘導体、それらの製造方法、並びにそれらの使用
Höfle et al. Epothilone AD and their thiazole-modified analogs as novel anticancer agents
FI93014B (fi) Sorafeeni, menetelmä sen valmistamiseksi ja sen käyttö kasvitautien torjumiseksi
Fang et al. Two New Components of the Aspochalasins Produced by Aspergillm sp.
KR102012416B1 (ko) 치마 버섯 균주 배양 추출물을 함유하는 항균성 조성물 및 이의 제조 방법
JPH024785A (ja) ストレプトミセス属からの新規なフラン類およびラクトン類
NZ230596A (en) Soraphen derivatives, myxobacteria which produce them, and their use for combatting plant diseases
JP2005511774A (ja) 抗菌化合物
Cho Isolation of 3-Galloylprocyanidin B 3, a Glucosyltransferase Inhibitor from the Korean Green Tea Leaves
JP3435741B2 (ja) 新規物質及び該物質を生産する微生物
CN102101863B (zh) 新型环氧噻酮化合物及其制备方法和用途
JP2011097871A (ja) アクチノマデュラ属に属する新規微生物、その微生物が産生する新規化合物、及びその化合物を有効成分とする医薬
JP4224404B2 (ja) 破骨細胞分化抑制物質
JP2020029406A (ja) 植物成長調節剤
JP2009510135A (ja) バーコルデリア・リゾキシナから得られる抗有糸分裂性リゾキシン誘導体、その製造方法及びその使用
WO1996026199A1 (en) Active bio-compounds
KR20050019892A (ko) 에포틸론 씨, 디, 이 및 에프, 그 제조방법 및 세포증식억제제와 식물 위생제로서의 이들의 용도
JPH07505781A (ja) 抗菌的に活性な化合物
JPS58201795A (ja) 植物抽出物およびそれを有効成分として含有する農園芸用殺菌組成物
JP2003342277A (ja) フロピリジン抗細菌剤
MXPA99004471A (en) Epothilone c, d, e and f, production process, and their use as cytostatic as well as phytosanitary agents